Clinical and laboratory follow-up resulted in a different diagnosis in one quarter of children with acute disseminated encephalomyelitis.
Investigators from a multicenter consortium collected serum from 210 children with acute demyelinating syndromes. At presentation, 60 were diagnosed with acute disseminated encephalomyelitis (ADEM), 101 with clinically isolated syndrome (CIS), and 12 with neuromyelitis optic spectrum disorder (NMOSD). After 24 months, the ADEM diagnosis still applied in 46; the other 14 had recurrent events (most often multiphasic ADEM). Of those with CIS, 54 had further demyelinating events, 40 of whom were diagnosed with multiple sclerosis (MS). The number with NMOSD diagnosis increased to 16 after 2 years.
Myelin oligodendrocyte glycoprotein antibody (MOG-ab) titers were detected in 31% of patients, more commonly those presenting with an ADEM phenotype or…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)